As reported on PharmaBiz, a major UK breast cancer study has passed a significant recruitment milestone, with more than 1,000 patients now participating in research that could dramatically reduce the time required for postoperative radiotherapy.
The FAST-Forward Boost trial is evaluating whether breast cancer radiotherapy, including an additional dose targeted to the area where a tumor was removed, can be completed in just five treatment sessions over one week. Current treatment schedules typically require between three and five weeks of hospital visits, depending on whether the boost dose is administered separately.
Aiming to Reduce Treatment Burden
Researchers hope the shortened regimen will provide the same cancer control and safety outcomes as conventional treatment while significantly reducing the burden on patients.
If proven effective, the approach could eliminate 10 or more hospital appointments for many patients. Fewer visits may lessen travel costs, reduce disruption to work and family life, and improve overall treatment convenience. The strategy could also increase capacity within the UK’s National Health Service (NHS) by allowing radiotherapy departments to treat more patients.
Building on Previous Research
The study expands on evidence from two earlier landmark investigations.
One previous trial demonstrated that standard breast radiotherapy could be safely condensed from 15 treatments to five without compromising effectiveness. Another explored integrating the tumor-bed boost into the main radiotherapy course rather than delivering it afterward.
The FAST-Forward Boost trial combines these concepts, directly comparing a five-treatment schedule delivered over one week with the current 15-treatment standard approach.
Nationwide Recruitment Effort
The trial is currently active at 39 hospitals and cancer centers across the United Kingdom, reflecting a broad national effort to improve breast cancer care.
Approximately 37,000 people in the UK receive breast radiotherapy each year to reduce the risk of disease recurrence. For many of these patients, a shorter yet equally effective treatment course could represent a meaningful improvement in quality of life.
Focus on Patient-Centered Care
Investigators say the study is designed not only to evaluate clinical outcomes but also to improve the patient experience. Radiotherapy can cause side effects that affect daily life during and after treatment, making efforts to streamline care particularly important.
Researchers believe that shortening treatment schedules, while maintaining efficacy and safety, could help patients spend less time in healthcare settings and more time focused on recovery and everyday activities.
Long-Term Follow-Up Planned
The National Institute for Health and Care Research (NIHR) has invested £3.9 million in the project, which is being led by researchers at The Institute of Cancer Research in London in collaboration with clinical teams across the UK.
The trial ultimately aims to enroll 4,830 participants by 2028. All patients will be monitored for five years after treatment, allowing investigators to assess long-term outcomes, side effects, and cancer control. Final results are expected in 2033.
If successful, the study could support a new standard of care in which breast cancer radiotherapy is delivered in a fraction of the time currently required, offering a more convenient treatment pathway for thousands of patients each year.
